Dilbert Creator to Undergo Cancer Treatment
Scott Adams, the creator of “Dilbert,” announced on Monday that he intends to receive treatment for metastatic prostate cancer using Pulvict, a drug recently cleared by the FDA. This decision came after he expressed difficulty in setting up appointments, particularly to the Trump administration.
On Sunday, Adams shared with X that his healthcare provider, Kaiser of Northern California, had accepted his application for the medication but had complicated its administration—skipping the straightforward IV schedule.
“On Monday, I’ll be reaching out to President Trump with a simple request: I need it,” he declared.
Shortly after, Donald Trump Jr. responded, saying he would show this to his father, writing, “We’re all praying for you, keep fighting!”
By Sunday afternoon, Trump took to Truth Social, sharing Adams’ tweet and commenting, “I agree with that!”
Health and Human Services Secretary Robert F. Kennedy Jr. also engaged, expressing the desire to contact Adams and noting Trump’s willingness to assist.
Venture capitalist Chamath Palihapitiya connected Kennedy and Adams via text. In addition, Dr. Afshain Emrani of FACC reached out to inform Adams he had alerted the medical director at Kaiser regarding the urgency of the situation.
On Monday, during his regular stream, Coffee with Scott Adams, he mentioned receiving calls on Sunday from Trump Jr., Kennedy Jr., and Dr. Mehmet Oz, all inquiring about how they could help.
“You may have seen that President Trump, perhaps the greatest president ever, responded to my public message on X yesterday,” Adams noted. “His support was passionate and, wow, he was really involved!”
Adams updated his viewers on the progress made since the previous day.
“Everything is now under control and heading in the right direction,” he stated, mentioning that he had gained additional support beyond Kaiser.
Regarding Pulvict, he clarified that the drug cannot be administered immediately after a request. “It requires a specialized setting for nuclear medicine,” he explained. “This means it can’t just be done at a clinic; it needs to be customized for the patient.” He added, “Different patients require different formulations, tailored to their specific needs.” This process usually takes about two weeks, though efforts are being made to expedite it.
Adams has an appointment set with a specialist on Monday, which he hopes will begin his healing journey.
“Maybe I was unaware that they were working on this, but I think I should’ve been consulted first. This morning, I scheduled a discussion with their expert as soon as this wrap-up is complete. I believe this is a step in the right direction,” he remarked.
He expressed concerns about not knowing if the treatment process had even started, which only compounded his worries. “The uncertainty is tough; you don’t know who to turn to or if anything is moving forward,” he added.
